Download
1 / 5
50 likes | 59 Views
CRISPR has already shown promise in the field of biomedicine, initially by showing improvement in genome editing in bacteria and then quickly in humans and a wide range of other animals. While it will take some time before CRISPR becomes more well-known among scientists and ultimately among the general public, ushering in the CRISPR revolution.
E N D
Future shifts to in vivo genome editing for a potential treatment strategy CRISPR has already shown promise in the field of biomedicine, initially by showing improvement in genome editing in bacteria and then quickly in humans and a wide range of other animals. While it will take some time before CRISPR becomes more well-known among scientists and ultimately among the general public, ushering in the CRISPR revolution.
Read more- Gene Editing: a hope for Sickle cell anemia So far, ex vivo applications have focused on using CRISPR tools to generate allogeneic, or "off-the-shelf," cell therapies for hematologic malignancies like non-lymphoma, Hodgkin's, and multiple myeloma, as well as leukemias and lymphomas. Ex vivo CRISPR editing presents fewer safety and delivery challenges than in vivo applications, and CRISPR editing of cell therapies may be viewed as a safer alternative to untargeted viral integration-based approaches that preceded it
What to expect in the coming years? • Given CRISPR's advancements to date and enormous possibilities, the following key trends will make the technology value in the future. • This cutting-edge CRISPR technique, dubbed "prime editing," would make it possible to add or remove particular sequences at genomic regions with reduced side effects. Prime editors provide more precise editing and targeting options.
